Loss of the Metastasis Suppressor NME1, But Not of Its Highly Related Isoform NME2, Induces a Hybrid Epithelial-Mesenchymal State in Cancer Cells.
cancer
epithelial–mesenchymal transition
epithelium
metastasis
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
02 Apr 2021
02 Apr 2021
Historique:
received:
02
03
2021
revised:
29
03
2021
accepted:
30
03
2021
entrez:
30
4
2021
pubmed:
1
5
2021
medline:
19
5
2021
Statut:
epublish
Résumé
Epithelial-mesenchymal transition (EMT) is important for the initial steps of metastasis. Although it is well accepted that the nucleoside diphosphate kinase NME1 is a metastasis suppressor, its effect on EMT remains poorly documented, as does that of its closely related isoform, NME2. Here, by using gene silencing, inactivation and overexpression strategies in a variety of cellular models of cancer, we show that NME1 is a powerful inhibitor of EMT. Genetic manipulation of NME2, by contrast, had no effect on the EMT phenotype of cancer cells, indicating a specific function of NME1 in EMT regulation. Loss of NME1 in epithelial cancer cells resulted in a hybrid phenotype intermediate between epithelial and mesenchymal cells, which is known to be associated with cells with a highly metastatic character. Conversely, overexpression of NME1 in mesenchymal cancer cells resulted in a more epithelial phenotype. We found that NME1 expression was negatively associated with EMT markers in many human cancers and was reduced in human breast tumor cell lines with the aggressive 'triple-negative' phenotype when compared to human breast tumor cell lines positive for estrogen receptor. We show that NME1, but not NME2, is an inhibitor of essential concerted intracellular signaling pathways involved in inducing EMT, including the AKT and MAPK (ERK, p38, and JNK) pathways. Additionally, NME1 depletion considerably altered the distribution of E-cadherin, a gatekeeper of the epithelial phenotype, shifting it from the plasma membrane to the cytosol and resulting in less E-cadherin on the cell surface than in control cells. Functional aggregation and dispersion assays demonstrated that inactivation of
Identifiants
pubmed: 33918324
pii: ijms22073718
doi: 10.3390/ijms22073718
pmc: PMC8038181
pii:
doi:
Substances chimiques
Cadherins
0
NM23 Nucleoside Diphosphate Kinases
0
NME1 protein, human
EC 2.7.4.6
NME2 protein, human
EC 2.7.4.6
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Cancéropole-Ile de France
ID : n° 2015-1-EMERG-25-INSERM 6-1
Organisme : PLAN CANCER
ID : Project C19048DS
Références
J Bioenerg Biomembr. 2000 Jun;32(3):247-58
pubmed: 11768308
J Biol Chem. 2010 Dec 10;285(50):38765-71
pubmed: 20884616
Oncogene. 2016 Jan 21;35(3):344-57
pubmed: 25893299
Cold Spring Harb Perspect Biol. 2009 Dec;1(6):a003129
pubmed: 20457567
J Biol Chem. 2009 Dec 11;284(50):34986-97
pubmed: 19846557
Virology. 2017 Jun;506:110-120
pubmed: 28376369
J Cell Biol. 1998 Aug 24;142(4):1105-19
pubmed: 9722621
Cancer Res. 2015 May 1;75(9):1789-800
pubmed: 25744723
Nature. 2012 Apr 18;486(7403):346-52
pubmed: 22522925
J Bioenerg Biomembr. 2003 Feb;35(1):19-30
pubmed: 12848338
Oncogene. 2014 Sep 4;33(36):4508-4520
pubmed: 24096484
Cancer Metastasis Rev. 2012 Dec;31(3-4):593-603
pubmed: 22706779
Clin Exp Metastasis. 2008;25(2):131-8
pubmed: 18058029
Int J Cancer. 1995 Mar 16;60(6):837-42
pubmed: 7896455
PLoS One. 2013;8(1):e53532
pubmed: 23341946
Nat Cell Biol. 2000 Feb;2(2):84-9
pubmed: 10655587
Science. 2014 Jun 27;344(6191):1510-5
pubmed: 24970086
Biochem Biophys Res Commun. 1993 Aug 31;195(1):336-45
pubmed: 8395830
Cancer Res. 2019 Sep 15;79(18):4689-4702
pubmed: 31311812
Cancer Res. 2017 Nov 15;77(22):6415-6428
pubmed: 28947416
Nat Cell Biol. 2006 Nov;8(11):1223-34
pubmed: 17060906
Cell. 2017 Feb 9;168(4):670-691
pubmed: 28187288
Int J Oncol. 1997 Nov;11(5):965-70
pubmed: 21528291
Arch Virol. 2019 May;164(5):1271-1285
pubmed: 30859475
Nucleic Acids Res. 2014 Oct;42(18):11589-600
pubmed: 25249619
Cancer Res. 2012 Jun 15;72(12):2917-23
pubmed: 22659456
Front Oncol. 2015 Jul 20;5:155
pubmed: 26258068
Sci Signal. 2014 Sep 30;7(345):ra91
pubmed: 25270257
Genes Dev. 2013 Oct 15;27(20):2192-206
pubmed: 24142872
Trends Cell Biol. 2019 Mar;29(3):212-226
pubmed: 30594349
Mol Cell Biol. 2004 Nov;24(21):9630-45
pubmed: 15485929
Cell Rep. 2015 Jan 13;10(2):131-9
pubmed: 25578726
Nat Commun. 2016 May 10;7:11479
pubmed: 27161491
Cold Spring Harb Perspect Biol. 2018 Mar 1;10(3):
pubmed: 28507022
J Biol Chem. 2003 Dec 26;278(52):52412-24
pubmed: 14561752
Clin Cancer Res. 2016 Feb 1;22(3):609-20
pubmed: 26420858
J Natl Cancer Inst. 1988 Apr 6;80(3):200-4
pubmed: 3346912
PLoS One. 2015 Feb 20;10(2):e0115968
pubmed: 25700270
Clin Exp Pharmacol Physiol. 2018 Dec;45(12):1317-1324
pubmed: 29956840
Oncogene. 2010 Apr 8;29(14):2118-29
pubmed: 20101217
Nat Rev Mol Cell Biol. 2019 Feb;20(2):69-84
pubmed: 30459476
Oncotarget. 2016 May 10;7(19):27067-84
pubmed: 27008704
Gastroenterology. 2012 Apr;142(4):886-896.e9
pubmed: 22240480
Cancer Res. 2001 Mar 1;61(5):2320-7
pubmed: 11280805
Nat Methods. 2012 Jun 28;9(7):676-82
pubmed: 22743772
BMC Cell Biol. 2011 May 17;12:20
pubmed: 21586144
Int J Cancer. 2012 Dec 15;131(12):2852-62
pubmed: 22511072
J Cell Sci. 2012 Sep 1;125(Pt 17):4137-46
pubmed: 22685328
Semin Cancer Biol. 2019 Oct;58:1-10
pubmed: 30453041
Cancer Res. 2010 Oct 1;70(19):7710-22
pubmed: 20841469
Cell Death Dis. 2013 Nov 07;4:e915
pubmed: 24201814
Cancer Discov. 2012 May;2(5):401-4
pubmed: 22588877
Int J Cancer. 1997 Oct 9;73(2):297-302
pubmed: 9335458
Cancer Res. 2015 Jul 1;75(13):2749-59
pubmed: 25948589
Carcinogenesis. 2011 Aug;32(8):1133-42
pubmed: 21504894
Nat Cell Biol. 2000 Feb;2(2):76-83
pubmed: 10655586
J Natl Cancer Inst. 2005 Jun 1;97(11):836-45
pubmed: 15928304
Nat Rev Cancer. 2013 Feb;13(2):97-110
pubmed: 23344542
PLoS One. 2011 Apr 07;6(4):e18645
pubmed: 21490937
Nat Commun. 2015 Feb 11;6:6139
pubmed: 25669750
Nature. 2018 Apr;556(7702):463-468
pubmed: 29670281
Mol Cell Biochem. 2009 Sep;329(1-2):51-62
pubmed: 19387795
Mol Cell Biol. 2015 Mar;35(6):1001-13
pubmed: 25582197
Int J Cancer. 2001 Sep 1;93(5):644-52
pubmed: 11477573
Clin Cancer Res. 1999 Dec;5(12):4301-7
pubmed: 10632374
Int J Mol Sci. 2019 Apr 29;20(9):
pubmed: 31035668
Proc Natl Acad Sci U S A. 2017 Mar 21;114(12):E2337-E2346
pubmed: 28270621
Cell. 2004 Jun 25;117(7):927-39
pubmed: 15210113
Nat Commun. 2018 Nov 27;9(1):5005
pubmed: 30479345
J Clin Invest. 1992 Mar;89(3):919-24
pubmed: 1311721
PLoS One. 2015 May 28;10(5):e0126522
pubmed: 26020648
Sci Signal. 2013 Apr 02;6(269):pl1
pubmed: 23550210
Sci Rep. 2017 Jan 17;7:40633
pubmed: 28094783
Oncogene. 2007 Oct 25;26(49):6979-88
pubmed: 17486063
Mol Oncol. 2016 Feb;10(2):253-71
pubmed: 26514616
J Clin Pathol. 2008 May;61(5):615-20
pubmed: 18156431
PLoS Comput Biol. 2015 Nov 10;11(11):e1004569
pubmed: 26554584
Cell. 2016 Jun 30;166(1):21-45
pubmed: 27368099
Oncotarget. 2018 May 1;9(33):23264-23273
pubmed: 29796187
Proc Natl Acad Sci U S A. 2013 Nov 5;110(45):18144-9
pubmed: 24154725